Increased Light Exposure Consolidates Sleep and Strengthens Circadian Rhythms in Severe Alzheimer's Disease Patients

2003 ◽  
Vol 1 (1) ◽  
pp. 22-36 ◽  
Author(s):  
Sonia Ancoli-Israel ◽  
Philip Gehrman ◽  
Jennifer L. Martin ◽  
Tamar Shochat ◽  
Matthew Marler ◽  
...  
2022 ◽  
Vol 12 ◽  
Author(s):  
Riccardo Cremascoli ◽  
Davide Sparasci ◽  
Gianluca Giusti ◽  
Stefania Cattaldo ◽  
Elisa Prina ◽  
...  

It is shown that the circadian system is affected in patients with Alzheimer’s disease (AD) even at an early stage of the disease and that such dysfunction may be detrimental to sleep, mood, and cognitive functioning. Light is a strong central modulator of the circadian rhythms and is potentially beneficial to mood and cognitive functioning via a direct effect or indirectly via its modulating effects on circadian rhythms. This study focuses on tracking the effect of light therapy on sleep quality, mood, and cognition in AD of mild/moderate severity. We performed a single-blind randomized controlled trial to investigate the effects of a light therapy treatment tailored to the individual circadian phase as measured by dim light melatonin onset (DLMO). Such a treatment induced an objective circadian phase shift consistent with the melatonin phase response curve to light exposure, led to a shortening of the phase angle DLMO-falling asleep time, and was associated with an improvement in subjective sleep quality and cognitive performance.


2021 ◽  
Vol 17 (S5) ◽  
Author(s):  
Chiara La Morgia ◽  
Micaela Mitolo ◽  
Aurelia Santoro ◽  
Martina Romagnoli ◽  
Michelangelo Stanzani Maserati ◽  
...  

2022 ◽  
Vol 23 (1) ◽  
pp. 504
Author(s):  
Xuemin Peng ◽  
Rongping Fan ◽  
Lei Xie ◽  
Xiaoli Shi ◽  
Kun Dong ◽  
...  

Type 2 diabetes mellitus (T2DM) patients are at a higher risk of developing Alzheimer’s disease (AD). Mounting evidence suggests the emerging important role of circadian rhythms in many diseases. Circadian rhythm disruption is considered to contribute to both T2DM and AD. Here, we review the relationship among circadian rhythm disruption, T2DM and AD, and suggest that the occurrence and progression of T2DM and AD may in part be associated with circadian disruption. Then, we summarize the promising therapeutic strategies targeting circadian dysfunction for T2DM and AD, including pharmacological treatment such as melatonin, orexin, and circadian molecules, as well as non-pharmacological treatments like light therapy, feeding behavior, and exercise.


2012 ◽  
Vol 236 (2) ◽  
pp. 249-258 ◽  
Author(s):  
Marilyn J. Duncan ◽  
J. Tyler Smith ◽  
Kathleen M. Franklin ◽  
Tina L. Beckett ◽  
M. Paul Murphy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document